| Company Name: |
Bide Pharmatech Ltd.
|
| Tel: |
400-164-7117 13681763483 |
| Email: |
product02@bidepharm.com |
| Products Intro: |
Product Name:2,2-Dimethyl-4-oxo-3,8,11,14,17,20,23-heptaoxa-5-azapentacosan-25-yl 4-methylbenzenesulfonate
CAS:1292268-14-4
Purity:98% Package:100mg;250mg;1g Remarks:BD01197368
|
t-Boc-N-Amido-PEG7-Tos manufacturers
- Boc-NH-PEG7-Tos
-
- $37.00 / 10mg
-
2025-09-17
- CAS:1292268-14-4
- Min. Order:
- Purity: 95.17%
- Supply Ability: 10g
- NHBoc-PEG7-Tos
-
- $0.00 / 1g
-
2025-06-07
- CAS:1292268-14-4
- Min. Order: 1g
- Purity: >98.00%
- Supply Ability: 1g
|
| | t-Boc-N-Amido-PEG7-Tos Basic information |
| Product Name: | t-Boc-N-Amido-PEG7-Tos | | Synonyms: | t-Boc-N-Amido-PEG7-Tos;Boc-NH-PEG7-Tos;5,8,11,14,17,20-Hexaoxa-2-azadocosanoic acid, 22-[[(4-methylphenyl)sulfonyl]oxy]-, 1,1-dimethylethyl ester;NHBoc-PEG7-Tos;Boc-NH-PEG-7-Tos,inhibit,Inhibitor,BocNHPEG7Tos,PROTAC Linkers,Boc NH PEG7 Tos;2,2-Dimethyl-4-oxo-3,8,11,14,17,20,23-heptaoxa-5-azapentacosan-25-yl 4-methylbenzenesulfonate;Tos-PEG7-NH-Boc | | CAS: | 1292268-14-4 | | MF: | C26H45NO11S | | MW: | 579.7 | | EINECS: | | | Product Categories: | | | Mol File: | 1292268-14-4.mol |  |
| | t-Boc-N-Amido-PEG7-Tos Chemical Properties |
| Boiling point | 656.0±55.0 °C(Predicted) | | density | 1.155±0.06 g/cm3(Predicted) | | solubility | Soluble in DMSO, DCM, DMF | | pka | 12.23±0.46(Predicted) |
| | t-Boc-N-Amido-PEG7-Tos Usage And Synthesis |
| Description | t-Boc-N-Amido-PEG7-Tos is a PEG linker containing a tosyl group and Boc-protected amine group. The hydrophilic PEG spacer increases the water solubility of a compound in aqueous media. The tosyl group is a very good leaving group for nucleophilic substitution reactions. The Boc group can be deprotected under mild acidic conditions to form a free amine. | | Uses | Boc-NH-PEG7-Tos is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs[1]. | | IC 50 | PEGs | | References | [1] An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562 DOI:10.1016/j.ebiom.2018.09.005 |
| | t-Boc-N-Amido-PEG7-Tos Preparation Products And Raw materials |
|